Lupus Science and Medicine (May 2024)
402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus
Abstract
No abstracts available.
